Matthew Strobeck - May 21, 2024 Form 4 Insider Report for BIODESIX INC (BDSX)

Role
Director
Signature
/s/ Robin H. Cowie as Attorney-in-Fact for Matthew Strobeck
Stock symbol
BDSX
Transactions as of
May 21, 2024
Transactions value $
$0
Form type
4
Date filed
5/23/2024, 07:15 PM
Previous filing
Apr 9, 2024
Next filing
May 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDSX Common Stock Options Exercise +52.2K +155.64% 85.7K May 23, 2024 By Birchview Capital Separately Managed Account F1, F2
transaction BDSX Common Stock Options Exercise +296K +13% 2.57M May 23, 2024 By Birchview Fund LLC F1, F2
holding BDSX Common Stock 2.54M May 21, 2024 Direct
holding BDSX Common Stock 119K May 21, 2024 By UTMA Account F3
holding BDSX Common Stock 119K May 21, 2024 By UTMA Account F3
holding BDSX Common Stock 119K May 21, 2024 By UTMA Account F3
holding BDSX Common Stock 119K May 21, 2024 By UTMA Account F3
holding BDSX Common Stock 40.7K May 21, 2024 By Clajer Capital LLC F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDSX Restricted Stock Units Award $0 +53.7K $0.00 53.7K May 21, 2024 Common Stock 53.7K Direct F5, F6, F7
transaction BDSX Stock Options (Right to Buy) Award $0 +37.1K $0.00 37.1K May 21, 2024 Common Stock 37.1K $1.57 Direct F8
transaction BDSX Series A Non-Voting Convertible Preferred Stock Options Exercise $0 -1.3K -100% $0.00* 0 May 23, 2024 Common Stock 52.2K By Birchview Capital Separately Managed Account F1, F2
transaction BDSX Series A Non-Voting Convertible Preferred Stock Options Exercise $0 -7.39K -100% $0.00* 0 May 23, 2024 Common Stock 296K By Birchview Fund LLC F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024.
F2 The Reporting Person has sole voting and dispositive power with respect to shares held by each of Birchview Fund LLC and the Birchview Capital Separately Managed Account in his capacity as Manager of such entities. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3 The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4 The Reporting Person is an affiliate of Clajer Capital LLC. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F5 Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Common Stock.
F6 These RSUs will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period.
F7 Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.
F8 This option will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, this option will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period.